Waystar to Announce Second Quarter 2024 Financial Results on August 7, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LEHI, Utah and LOUISVILLE, Ky., July 17, 2024 /PRNewswire/ — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, announced today it will report financial results for the second quarter ended June 30, 2024, after market close on Wednesday, August 7, 2024. Waystar’s financial results will be discussed on a conference call scheduled at 4:30 p.m. Eastern Time that same day.

A live audio webcast of the conference call will be available on Waystar’s investor relations website at https://investors.waystar.com/news-events/events. The webcast will be archived on the site for those unable to listen in real-time.

About Waystar
Waystar’s mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar’s enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Media Contact
Kristin Lee
kristin.lee@waystar.com 

Investor Contact
Sandy Draper
investors@waystar.com
502-238-9511

View original content:https://www.prnewswire.com/news-releases/waystar-to-announce-second-quarter-2024-financial-results-on-august-7-2024-302199690.html

SOURCE Waystar

Staff

Recent Posts

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition…

3 hours ago

Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader…

3 hours ago

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or…

3 hours ago

Parexel Showcases Oncology Expertise at ASCO 2025; Company Selected to Present Five Posters at World’s Largest Oncology Event

Parexel also launching a comprehensive Radiopharmaceuticals report at the meeting Onsite Parexel experts include recently…

3 hours ago

Lantern’s Cancer Program Reaches 1 Million Member Milestone

Lantern also announces clinical team and partner expansion to deliver accelerated treatmentDALLAS, May 29, 2025…

3 hours ago